Alzheimer's Psychosis Studies Should Measure Improved Functional Status
Executive Summary
Studies of drugs for psychosis related to Alzheimer's disease should measure improvement in patients' functional status as well as amelioration of symptoms of psychosis, FDA's Psychopharmacologic Drugs Advisory Committee agreed at its March 9 meeting.
You may also be interested in...
J&J Product Targeting Histamine H3 Receptor Moves Into Clinic
Johnson & Johnson is moving a drug candidate targeting the histamine H3 receptor into clinical development in half the time it has historically taken to advance a candidate, J&J Pharmaceuticals Group Worldwide Chairman William Weldon told an April 18 teleconference.
J&J Product Targeting Histamine H3 Receptor Moves Into Clinic
Johnson & Johnson is moving a drug candidate targeting the histamine H3 receptor into clinical development in half the time it has historically taken to advance a candidate, J&J Pharmaceuticals Group Worldwide Chairman William Weldon told an April 18 teleconference.
Agitation Should Be Called Nonspecific Symptom Across Diseases - Lilly
Agitation should be defined as a nonspecific symptom across a range of disease states, Lilly Zyprexa Product Team Leader Alan Breier, MD, proposed at a March 9 meeting of the FDA Psychopharmacologic Drugs Advisory Committee.